Parkinson Disease Pathogenic Variants

Samantha Hong; Mathew J. Koretsky; Jens Lichtenberg; Hampton L Leonard; Vanessa Pitz; as the Global Parkinson's Genetics Program (GP2)

doi:10.1212/nxg.0000000000200379

April 13, 2026Neurology GeneticsOpen Access

Parkinson Disease Pathogenic Variants

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to assess genotyping success of the NeuroBooster array and analyze pathogenic variant frequencies in Parkinson disease across different ancestries.
Evaluated genotyping success rate of the NeuroBooster array
Analyzed frequencies of pathogenic variants
Included participants from diverse ancestry backgrounds
Identified varying frequencies of pathogenic variants across different ancestries
Showed successful genotyping with the NeuroBooster array
Provided insights into the role of ancestry in Parkinson disease variant distribution

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Evaluates genotyping efficiency and variant frequencies in Parkinson disease across ancestries, highlighting diversity implications.

Abstract

Known pathogenic variants (PVs) in Parkinson disease (PD) contribute to disease development but have yet to be fully explored by arrays on a large scale. This study evaluated genotyping success of the NeuroBooster array (NBA) and determined the frequencies of PVs across ancestries.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hong et al. (2026) studied this question.

synapsesocial.com/papers/69e07c1e2f7e8953b7cbd8f1 https://doi.org/10.1212/nxg.0000000000200379

View Full Paper

Ask AI

Bookmark

Share

Parkinson Disease Pathogenic Variants

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Parkinson Disease Pathogenic Variants

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading